Retrospective analysis of a cohort of HIV-infected patients on antiretroviral therapy in Abidjan (2003 to 2017)

Lenoir T. A. Djadji; Awa N. G. Silue; Geneviève A. I. N’guessan; Gisèle N'Doua S. Kouakou; Serge P. Eholie

doi:10.18203/2319-2003.ijbcp20231112

Authors

Lenoir T. A. Djadji Department of Pharmacology, Faculty of Pharmaceutical and Biological Sciences, Felix Houphouet-Boigny University, Abidjan, Côte d'Ivoire
Awa N. G. Silue Department of Pharmacology, Faculty of Pharmaceutical and Biological Sciences, Felix Houphouet-Boigny University, Abidjan, Côte d'Ivoire
Geneviève A. I. N’guessan Department of Pharmacology, Faculty of Pharmaceutical and Biological Sciences, Felix Houphouet-Boigny University, Abidjan, Côte d'Ivoire
Gisèle N'Doua S. Kouakou Department of Pharmacology, Faculty of Pharmaceutical and Biological Sciences, Felix Houphouet-Boigny University, Abidjan, Côte d'Ivoire
Serge P. Eholie Department of Pharmacology, Faculty of Pharmaceutical and Biological Sciences, Felix Houphouet-Boigny University, Abidjan, Côte d'Ivoire

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20231112

Keywords:

Life expectancy, HIV, ART, University Teaching Hospital of Treichville

Abstract

Background: Antiretroviral therapy (ART) has been successful in improving clinical outcomes for HIV-positive patients, but efforts are needed to improve life expectancy and quality of life. This study aimed to analyze a long-term ART cohort and assess patients' life expectancy.

Methods: A retrospective cohort study was conducted at the infectious and tropical diseases department of the University Teaching Hospital of Treichville from 2003 to 2017. Data analysis was done using VBA access and XLSTAT 2018 excel software. Patients on post-exposure chemoprophylaxis and prevention of mother-to-child transmission were excluded.

Results: Out of 19,567 patient records, 49.60% were included, 72.43% were in 1^st line, and 50.10% were over 50 years old, mostly female 58.49%, 98.4% HIV1. 74.31% had a CD4/mm³ (Nadir) count <350. The patients were essentially on the 2IN+INN regimen (72.31%), TDF + XTC + EFV (20.57%). The average duration under treatment 6.15 [0-13.67] ±3.94 years, the average duration under a line of treatment 4.33 [0-14.04] ±2.96 years. Life expectancy was 10.37 years. It is higher in patients on 2IN+IPr (12.21 years) versus 10.12 years in patients on 2IN+INN. The comparison of duration on a line according to the CD4 counts and the line of treatment did not show a significant difference p>0.05.

Conclusions: The study concluded that ART significantly improved the life expectancy of patients, adherence could be improved to further enhance the benefits of ART. The use of new combinations of ART may reduce events related to non-compliance.

Metrics

Metrics Loading ...

References

ONUSIDA. Rapport sur l'épidémie mondiale de VIH/SIDA 2010. Genève: Programme commun des Nations unies sur le VIH/SIDA (ONUSIDA). 2010.

Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.

Harries AD, Zachariah R, Lawn SD, Rosen S. Strategies to improve patient retention on antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health. 2010;15(1):70-5.

Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010;11(7):510-8.

Nash D, Wu Y, Elul B, Hoos D, El Sadr W. Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries. AIDS. 2011;25(1):1523-33.

World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2016. Available at: https://www.who.int/publications/i/item/9789241549684. Accessed on 12 January 2023.

ONUSIDA. Rapport d'avancement sur la déclaration politique de 2011 sur le VIH/sida: Côte d'Ivoire. Genève, ONUSIDA. 2013.

Guaraldi G, Milic J, Mussini C, Falutz J. Long-term effectiveness of antiretroviral therapy in a cohort of HIV-infected patients: the challenge of aging. Clin Infect Dis. 2017;65(10):1671-8.

Sanne IM, Westreich D, Macphail AP, Rubel D, Majuba P, Van Rie A. Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc. 2009;12:38.

Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV. 2016;3(11):e510-20.

Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349-56.

Meloni ST, Chang CA, Eisen G, Jolayemi T, Banigbe B, Okonkwo PI, Kanki PJ. Long-term outcomes of antiretroviral therapy in a large HIV/AIDS care and treatment program in Nigeria. PloS One. 2016;13(7):e0197291.

World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2016. Available at: https://www.who.int/publications/i/item/9789241549684. Accessed on 07 December 2022.

Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119-29.

Kumarasamy N, Solomon S, Chaguturu SK, Mahajan AP, Flanigan TP, Balakrishnan P, et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS. 2003;17(15):2267-9.

Lohse N, Obel N, Kronborg G, Jørgensen LB, Pedersen C, Larsen CS, et al. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther. 2006;11(5):591-600.

Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet. 2008;371(9622):1443-51.

World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva: World Health Organization. 2013. Available at: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf. Consulté le 27/06/2017. Accessed on 07 December 2022.

Dalhatu I, Onotu D, Odafe S, Abiri O, Debem H, Agolory S, et al. Outcomes of Nigeria's HIV/AIDS Treatment Program for Patients Initiated on Antiretroviral Treatment between 2004-2012. PLoS One. 2016;11(11):e0165528.

Jiamton S, Inthawong D, Sanchiem W, Praparattanapan J, Chaiwarith R, Kotarathititum W, et al. Long-term outcomes of antiretroviral therapy in a national cohort of Thai patients with HIV infection. J Acquired Immune Deficiency Syndromes. 2009;51(5):463-70.

Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PloS one. 2013;8(12):e81355.

Günthard HF, Saag MS, Benson CA, Del Rio C, Eron JJ, Gallant JE, et al. A. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312(4):410-25.

Vitoria M, Granich R, Gilks CF, Gunneberg C. The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am J Clin Pathol. 2009;131(6):844-8.

Kebebew K, Dorigo O. The role of surgery in HIV care in sub-Saharan Africa. The Lancet HIV. 2019;6(8):e521-30.

Kumar P, Kumar R, Singh J, Virdi NK, Kaur J. HIV infection and oxidative stress: an overview. Indian J Clin Biochem. 2013;28(4):314-28.

Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, et al. Loss to follow-up in an international, multicentre observational study. HIV Med. 2010;11(5):375-87.

De Beaudrap P, Etard JF, Diouf A, Bonnet F, Renaud F, Ngom Gueye NF, et al. Association between line of treatment and mortality in HIV-positive patients on antiretroviral therapy in Côte d'Ivoire, 2000–14: a retrospective cohort analysis. The Lancet HIV. 2017;4(9):e399-408.

Wang X, Wu G, Zhang W, Guo F, Li Y, Zhou W, Lu H. The association between baseline HIV RNA level and CD4 cell count gain in HIV-positive patients on suppressive antiretroviral therapy. Medicine. 2015;94(45):e1991.